Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudarshan Pharma IndustriesBOM:543828 -5.00%69 EBITDA Margin % is 11.01% as of Mar. 2026, which is 228% above its 10-year median of 3.36. GuruFocus rates BOM:543828 with a GF Score™ of 69/100 and a GF Value™ of ₹6.52 (Significantly Overvalued). The stock has 14 warning signs investors should review. Among 1,578 Chemicals companies, Sudarshan Pharma Industries ranks worse than 54.94% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sudarshan Pharma Industries EBITDA Margin % Related Terms
Sudarshan Pharma Industries EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Sudarshan Pharma Industries's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudarshan Pharma Industries EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Sudarshan Pharma Industries's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sudarshan Pharma Industries's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudarshan Pharma Industries (BOM:543828) has a EBITDA Margin % of 11.01% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sudarshan Pharma Industries and its competitors. This is 228% above median its historical median of 3.36. Over the past decade, Sudarshan Pharma Industries' EBITDA Margin % has ranged from 1.29 to 8.54. According to the industry distribution chart, Sudarshan Pharma Industries ranks #867 out of 1578 companies in the Chemicals industry, placing it in the top 54.9%.
Is Sudarshan Pharma Industries' EBITDA Margin % too high?
Sudarshan Pharma Industries' current EBITDA Margin % of 11.01% is 228% above median its 10-year median of 3.36. Over the past 10 years, this metric has ranged from a low of 1.29 to a high of 8.54. The Chemicals industry median EBITDA Margin % is 9.68. Sudarshan Pharma Industries' value of 11.01% is 13.7% above this industry median. Based on the distribution chart, Sudarshan Pharma Industries ranks #867 out of 1578 companies in the Chemicals industry, which is below the industry midpoint. Overall, Sudarshan Pharma Industries has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sudarshan Pharma Industries' EBITDA Margin % compare to DOW?
According to the Chemicals industry distribution chart, Sudarshan Pharma Industries ranks #867 out of 1578 companies for EBITDA Margin %. This places Sudarshan Pharma Industries in the lower half of its industry. The industry median EBITDA Margin % is 9.68. Sudarshan Pharma Industries' value of 11.01% is 13.7% above this benchmark. Historically, Sudarshan Pharma Industries' own EBITDA Margin % has ranged from 1.29 to 8.54 over the past decade. While the company's 10-year median is 3.36 vs. the industry median of 9.68, Sudarshan Pharma Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.68, based on 1,578 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudarshan Pharma Industries's current EBITDA Margin % of 11.01% is 13.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sudarshan Pharma Industries and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudarshan Pharma Industries's current EBITDA Margin % is 11.01%, which is 228% above median its own 10-year median of 3.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudarshan Pharma Industries stock overvalued right now?
Based on GuruFocus' analysis, Sudarshan Pharma Industries (BOM:543828) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.52, compared to a current price of ₹32.49 — trading 398.3% above its estimated fair value. The current EBITDA Margin % is 11.01%, which is 228% above median its 10-year median of 3.36 and 13.7% above the Chemicals industry median of 9.68. Sudarshan Pharma Industries' overall GF Score™ is 69/100 with 14 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sudarshan Pharma Industries (BOM:543828), the current EBITDA Margin % is 11.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sudarshan Pharma Industries (BOM:543828) Overvalued in 2026?
Based on GuruFocus' analysis, Sudarshan Pharma Industries stock appears to be overvalued.
The current stock price of ₹32.49 is trading 398.3% above its estimated GF Value™ of ₹6.52.
GuruFocus considers Sudarshan Pharma Industries to be Significantly Overvalued.
Key valuation signals for BOM:543828:
EBITDA Margin %: 11.01% (228% above median its 10-year median of 3.36)
GF Value™: ₹6.52 vs. price of ₹32.49 (398.3% above fair value)
Industry Position: 13.7% above the Chemicals median (#867 of 1578)
No single metric tells the full story. See the BOM:543828 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sudarshan Pharma Industries Ltd operates in the pharmaceutical and chemical industries, focusing on specialty chemicals and intermediates used in pharmaceuticals, paints, food products, and adhesives. The Company has a presence domestically and internationally, participating regularly in trade fairs and exhibitions. The Company exports mainly to South East Asia, the Middle East, and North Africa. The Company also supplies generic pharmaceutical formulation as 'Make to order' for bulk supply to hospitals and related healthcare organisations. The company has one reportable segment of Specialty Chemicals.
69GF Score
Get the complete analysis for BOM:543828
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543828 has been successfully added to your 
